Hilary Kramer - 04 Sep 2025 Form 4 Insider Report for GT Biopharma, Inc. (GTBP)

Reporting relationship
Director
Issuer ticker
GTBP
Reported as of
04 Sep 2025
Net transaction value
$0
Source evidence Original filing metadata and source links for verification. 4 source fields
SEC form
4
Accepted by SEC
08 Sep 2025, 17:45:38 UTC
Prior SEC filing
03 Jun 2025
Source filing
View source filing
Reporting owner 1 detail
Reporting owner signature
/s/ Hilary Kramer

Key filing fact

Hilary Kramer filed Form 4 for GT Biopharma, Inc. (GTBP) on 08 Sep 2025.

Key facts

  • This page summarizes Hilary Kramer's Form 4 filing for GT Biopharma, Inc. (GTBP).
  • 1 reported transaction and 1 derivative row are listed below.
  • Accepted by SEC: 08 Sep 2025, 17:45.

Change

  • Previous filing in this sequence was filed on 03 Jun 2025.
  • Current net transaction value: $0.

Research use

  • This tells you what this filing adds before you inspect full transaction and derivative tables.
  • You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reporting Owners (1)

CIK 0002071192 Primary reporting owner

Kramer Hilary

Relationship
Director
Address
C/O GT BIOPHARMA, INC., 505 MONTGOMERY STREET, 10TH FLOOR, SAN FRANCISCO
Signature
/s/ Hilary Kramer
Signature date
08 Sep 2025

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

GTBP transaction Derivative

Option to purchase Common Stock

Award

Transaction value
$0
Shares
+31,250
Change %
Price
$0.000000
Shares after
31,250
Date
04 Sep 2025
Ownership
Direct
Underlying class
Common Stock
Underlying amount
31,250
Exercise price
$1.33
Footnotes
F1
* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

The options are fully vested and exercisable.

We use cookies and similar technologies to provide certain features, enhance the user experience and, if you allow them, measure engagement and deliver advertising. Analytics and marketing storage stay off until you grant consent. By clicking on "Agree and continue", you declare your consent to the use of the selected optional cookies. Manage preferences to update or revoke optional consent for future visits. For more information, see our Privacy Policy .